PMID- 17077526
OWN - NLM
STAT- MEDLINE
DCOM- 20070226
LR  - 20221207
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 29
IP  - 11
DP  - 2006 Nov
TI  - Effect of congestive heart failure on mexiletine pharmacokinetics in a Japanese 
      population.
PG  - 2267-9
AB  - OBJECTIVE: The goal of this study was to evaluate the influence of congestive 
      heart failure (CHF) on the clearance of mexiletine. METHODS: The mexiletine 
      clearance/bioavailability (CL/F) ratio was estimated in 584 inpatients receiving 
      mexiletine therapy. The study population consisted of 210 patients with CHF [CHF 
      group; 116 inpatients with New York Heart Association (NYHA) class I-II (group 
      NYHA I-II) CHF and 94 inpatients with NYHA class III-IV (group NYHA III-IV) CHF] 
      and 374 inpatients without CHF (Non-CHF group). Serum levels of mexiletine were 
      determined by high performance liquid chromatography (HPLC). RESULTS: Mexiletine 
      clearance was significantly lower in the CHF group when compared with the Non-CHF 
      group (0.264+/-0.093 vs. 0.393+/-0.082 l/h/kg, mean+/-S.D., p<0.05). Further, the 
      CL/F ratio was 50% lower in group NYHA III-IV when compared with the Non-CHF 
      group, and the CL/F ratio tended to change in inverse proportion to NYHA class. 
      CONCLUSION: CHF status significantly affects mexiletine clearance. Therefore, 
      dose adjustments and careful monitoring are likely required in CHF patients 
      receiving mexiletine.
FAU - Kobayashi, Mariko
AU  - Kobayashi M
AD  - Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied 
      Life Sciences, Japan.
FAU - Fukumoto, Kyoko
AU  - Fukumoto K
FAU - Ueno, Kazuyuki
AU  - Ueno K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 1U511HHV4Z (Mexiletine)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Arrhythmia Agents/administration & dosage/pharmacokinetics/therapeutic use
MH  - Asian People
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Drug Administration Schedule
MH  - Drug Monitoring/methods
MH  - Female
MH  - Heart Failure/*drug therapy/*metabolism
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Mexiletine/blood/*pharmacokinetics/therapeutic use
MH  - Severity of Illness Index
EDAT- 2006/11/02 09:00
MHDA- 2007/02/27 09:00
CRDT- 2006/11/02 09:00
PHST- 2006/11/02 09:00 [pubmed]
PHST- 2007/02/27 09:00 [medline]
PHST- 2006/11/02 09:00 [entrez]
AID - JST.JSTAGE/bpb/29.2267 [pii]
AID - 10.1248/bpb.29.2267 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2006 Nov;29(11):2267-9. doi: 10.1248/bpb.29.2267.